Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Chong Elise A.; Svoboda Jakub; Nasta Sunita Dwivedy; Landsburg Daniel J.; Winchell Nicole; Napier Ellen; Mato Anthony R.; Melenhorst J. Joseph; Ruella Marco; Lacey Simon F.; June Carl H.; Schuster Stephen J.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

【24h】

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

机译：顺序抗CD19定向嵌合抗原受体修饰的T细胞疗法（CART19）和PD-1与PEMBROLIZUAB的患者复发或难治性B细胞非霍奇金淋巴瘤患者

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共3页
作者
Chong Elise A.; Svoboda Jakub; Nasta Sunita Dwivedy; Landsburg Daniel J.; Winchell Nicole; Napier Ellen; Mato Anthony R.; Melenhorst J. Joseph; Ruella Marco; Lacey Simon F.; June Carl H.; Schuster Stephen J.;
展开▼
作者单位

Univ Penn Abramson Canc Ctr Lymphoma Program Philadelphia PA 19104 USA;

Univ Penn Abramson Canc Ctr Lymphoma Program Philadelphia PA 19104 USA;

Univ Penn Abramson Canc Ctr Lymphoma Program Philadelphia PA 19104 USA;

Univ Penn Abramson Canc Ctr Lymphoma Program Philadelphia PA 19104 USA;

Univ Penn Abramson Canc Ctr Lymphoma Program Philadelphia PA 19104 USA;

Univ Penn Abramson Canc Ctr Lymphoma Program Philadelphia PA 19104 USA;

Mem Sloan Kettering Canc Ctr Leukemia Serv CLL Program 1275 York Ave New York NY 10021 USA;

Univ Penn Ctr Cellular Immunotherapies Philadelphia PA 19104 USA;

Univ Penn Ctr Cellular Immunotherapies Philadelphia PA 19104 USA;

Univ Penn Ctr Cellular Immunotherapies Philadelphia PA 19104 USA;

Univ Penn Perelman Sch Med Ctr Cellular Immunotherapies Philadelphia PA 19104 USA;

Univ Penn Abramson Canc Ctr Lymphoma Program Philadelphia PA 19104 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [J] . Chong Elise A., Svoboda Jakub, Nasta Sunita Dwivedy, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：顺序抗CD19定向嵌合抗原受体修饰的T细胞疗法（CART19）和PD-1与PEMBROLIZUAB的患者复发或难治性B细胞非霍奇金淋巴瘤患者
2. Estimating Long-Term Survival for Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy: A Comparison of Standard and Mixture Cure Models [J] . Aasthaa Bansal, Vincent Lin, Sean D. Sullivan, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：None
3. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma [J] . Bone marrow transplantation . 2020,第6期

机译：在抗CD19嵌合抗原受体T细胞治疗中的PD-1抑制快速肿瘤回归耐火弥漫性大B细胞淋巴瘤
4. Main Issues and Current Strategies in Enhancing the Efficacy of Chimeric Antigen Receptor T-Cell Therapy among Tumor Treatments [C] . Zhengting He International Conference on Frontiers of Biological Sciences and Engineering . 2020

机译：提高嵌合抗原受体T细胞治疗肿瘤治疗疗效的主要问题及目前策略
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report [O] . Wen-ying Zhang, Yao Wang, Ye-lei Guo, 2016

机译：CD20导向的嵌合抗原受体修饰的T细胞在复发或难治性B细胞非霍奇金淋巴瘤患者中的治疗：IIa早期试验报告
7. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma [O] . Brian T. Hill, Zachary J. Roberts, Allen Xue, 2019

机译：在抗CD19嵌合抗原受体T细胞治疗中的PD-1抑制快速肿瘤回归耐火弥漫性大B细胞淋巴瘤

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

著录项

引文网络

相似文献

相关主题

期刊订阅